Wellington Management Group Portfolio holdings
Wellington Management Group, founded in 1928 by Walter L. Morgan and headquartered in Boston, Massachusetts, is one of the world’s largest independent asset management firms, overseeing trillions in assets for a diverse client base including pension funds, endowments, and mutual fund investors. Renowned for its active management approach, Wellington offers a broad range of investment strategies across equities, fixed income, multi-asset, and alternative investments, emphasizing deep research and long-term partnerships with clients. The firm gained early fame for launching the Wellington Fund, one of the first balanced mutual funds, and has since maintained a reputation for disciplined, collaborative portfolio management. With a global presence and a focus on customized solutions, Wellington remains a trusted name in institutional and retail investing.
Top Buys
| 1 |
Alphabet (Google) Class A
GOOGL
|
+$1.71B |
| 2 |
Eli Lilly
LLY
|
+$1.55B |
| 3 |
Tesla
TSLA
|
+$1.14B |
| 4 |
Boeing
BA
|
+$935M |
| 5 |
TE Connectivity
TEL
|
+$910M |
Top Sells
| 1 |
Apple
AAPL
|
+$1.79B |
| 2 |
Visa
V
|
+$1.57B |
| 3 |
General Dynamics
GD
|
+$1.55B |
| 4 |
Morgan Stanley
MS
|
+$1.29B |
| 5 |
Exelon
EXC
|
+$1.15B |
Sector Composition
| 1 | Technology | 24.19% |
| 2 | Healthcare | 17.87% |
| 3 | Financials | 14.67% |
| 4 | Consumer Discretionary | 10.1% |
| 5 | Industrials | 8.88% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1601
Aura Biosciences
AURA
$384M
| $1.08M | ﹤0.01% |
131,054
+14,662
| +13% | +$121K |
|
1602
Catalyst Pharmaceutical
CPRX
$2.44B
| $1.08M | ﹤0.01% |
51,550
-8,034
| -13% | -$168K |
|
1603
Howmet Aerospace
HWM
$74.9B
| $1.07M | ﹤0.01% |
9,816
+6,900
| +237% | +$755K |
|
1604
Flowers Foods
FLO
$2.9B
| $1.07M | ﹤0.01% |
+51,651
| New | +$1.07M |
|
1605
MacroGenics
MGNX
$100M
| $1.05M | ﹤0.01% |
323,857
+16,717
| +5% | +$54.3K |
|
1606
Broadridge
BR
$29.5B
| $1.05M | ﹤0.01% |
4,636
+1,026
| +28% | +$232K |
|
1607
Y-mAbs Therapeutics
YMAB
$390M
| $1.04M | ﹤0.01% |
133,263
-3,451
| -3% | -$27K |
|
1608
Arrowhead Research
ARWR
$4.11B
| $1.04M | ﹤0.01% |
55,396
-6,508
| -11% | -$122K |
|
1609
KalVista Pharmaceuticals
KALV
$705M
| $1.04M | ﹤0.01% |
122,863
+4,940
| +4% | +$41.8K |
|
1610
Utilities Select Sector SPDR Fund
XLU
$21.3B
| $1.03M | ﹤0.01% |
13,656
-3,722
| -21% | -$282K |
|
1611
Strategy Inc Common Stock Class A
MSTR
$94B
| $1.03M | ﹤0.01% |
3,565
-3,162
| -47% | -$916K |
|
1612
Kyverna Therapeutics
KYTX
$170M
| $1.03M | ﹤0.01% |
274,414
+39,291
| +17% | +$147K |
|
1613
IDEAYA Biosciences
IDYA
$2.16B
| $1.02M | ﹤0.01% |
39,790
-2,321
| -6% | -$59.7K |
|
1614
Acadia Pharmaceuticals
ACAD
$3.98B
| $1.02M | ﹤0.01% |
55,712
-6,873
| -11% | -$126K |
|
1615
C4 Therapeutics
CCCC
$189M
| $1.02M | ﹤0.01% |
283,705
-2,336
| -0.8% | -$8.41K |
|
1616
Taysha Gene Therapies
TSHA
$837M
| $1.01M | ﹤0.01% |
585,594
+122,402
| +26% | +$212K |
|
1617
Duolingo
DUOL
$14.1B
| $1.01M | ﹤0.01% |
3,115
-7,178
| -70% | -$2.33M |
|
1618
Rivian
RIVN
$16.3B
| $992K | ﹤0.01% |
74,568
+39,668
| +114% | +$528K |
|
1619
4D Molecular Therapeutics
FDMT
$318M
| $987K | ﹤0.01% |
177,279
+11,089
| +7% | +$61.8K |
|
1620
SPDR S&P International Small Cap ETF
GWX
$789M
| $975K | ﹤0.01% |
31,468
-5,539
| -15% | -$172K |
|
1621
Vodafone
VOD
$28.5B
| $970K | ﹤0.01% |
+114,300
| New | +$970K |
|
1622
Macy's
M
$4.54B
| $959K | ﹤0.01% |
56,637
-2,004,365
| -97% | -$33.9M |
|
1623
Virtu Financial
VIRT
$3.1B
| $954K | ﹤0.01% |
+26,751
| New | +$954K |
|
1624
Akebia Therapeutics
AKBA
$782M
| $954K | ﹤0.01% |
502,127
+97,409
| +24% | +$185K |
|
1625
LiveRamp
RAMP
$1.73B
| $951K | ﹤0.01% |
31,306
| – | – |
|